The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

A statewide grand jury didn’t find evidence that COVID-19 vaccine manufacturers broke federal or state laws when making and ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

With a state grand jury report released Wednesday, Florida Gov. Ron DeSantis doubled down on the message he delivered often ...

Moderna’s current price is less than $20 below the psychologically significant $50 price level. Traders often focus on these ...

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images) The stock price of Moderna saw a 12% jump on ...